Secondary prevention of prostate cancer through prostate-specific antigen (PSA)-based screening has been done on an ad hoc basis in the Caribbean by private practitioners, urologists and cancer societies since PSA was introduced into clinical practice in 1988 but despite this, almost 50% of men still present with symptomatic, locally advanced and metastatic disease in territories such as Jamaica [4]. Here, KLK3 is linked to cancer.